The newly public biopharmaceutical company launched by inside trader Sam Waksal had better come up with a drug for investor chest pains. At its initial public offering Wednesday, shares of the shady entrepreneur’s Kadmon Holdings LLC opened low and sank still lower, further decimating the holdings of pre-IPO investors who bought in at private sales...
read more
Source: New York Post